Skip to main content
Caplight Logo









Volastra Therapeutics

Volastra Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.volastratx.com/

Last Round

Series B

Sep 23, 2025

Total Funding Raised

$166.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Volastra Therapeutics is a biotechnology company that develops oncology therapeutics targeting chromosomal instability to treat metastatic cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

KIF18A inhibitorschromosomal instabilityCINoncology therapeuticssolid tumorsdrug discoverybiotechRb pathwayclinical-stage biotechbiomarker developmentsmall molecule therapeuticsprecision oncologypatient selectioncomputational biologydrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Volastra Therapeutics Comparables

Compare Volastra Therapeutics with similar companies based on industry and business-model similarity.

Volastra Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Simcere Pharmaceutical Group
76%
Apeiron Therapeutics
74%
China National Machinery Industry Corporation
74%

Volastra Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 23, 2025
Series AMar 7, 2023
SeedApr 6, 2021
SeedFeb 11, 2020

Key People

Founding team and executive leadership

Samuel Bakhoum

Chief Scientific Officer, Co-Founder And Board Member

Founding Team

David Southwell

Chief Executive Officer

Executive Team

Volastra Therapeutics Investors

Notable investors and investment history

Volastra Therapeutics investors
InvestorRounds
B Capital GroupSeries B
ARCH Venture PartnersSeed, Series A
Vida VenturesSeed, Series A
Droia VenturesSeed, Series A
Catalio Capital ManagementSeed, Series A
ARCH Venture PartnersSeed, Series A
Cornell University Office of University InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 78% MoM, reaching 4K.

  • May 31, 2026

    Two assets, VLS-1488 and Sovilnesib, granted designation by the FDA.

Volastra Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Volastra Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Volastra Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range41
Year Founded2019
Last FundingSep 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?